[Combination regimens in rheumatoid arthritis]

IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications

Arthritis associated with monoclonal gammapathy: clinical characteristics

Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis

In vivo migration of radiolabelled lymphocytes in rheumatoid synovial tissue engrafted in SCID mice: implication of beta 2 and beta 7-integrin

In vivo migration of tonsil lymphocytes in rheumatoid synovial tissue engrafted in SCID mice: involvement of LFA-1

Mononuclear cell retention in rheumatoid synovial tissue engrafted in severe combined immunodeficient (SCID) mice is up-regulated by tumour necrosis factor-alpha (TNF-alpha) and mediated through intercellular adhesion molecule-1 (ICAM-1)

Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis

Autoimmunity. Insights provided by the SCID mouse model

Kinetics of prolactin release in rheumatoid arthritis

Vasculitis and psoriatic arthritis associated with Down's syndrome

Rheumatoid factor associated with a secretory component in rheumatoid arthritis

Radiolabelled lymphocyte migration in rheumatoid synovitis

Expression of a multidrug resistance gene in human rheumatoid synovium

Human mucosyl lymphocyte marker expression in synovial fluid lymphocytes of patient with rheumatoid arthritis

Increased percentage of CD3+, CD57+ lymphocytes in patients with rheumatoid arthritis. Correlation with duration of disease

Serum levels of secretory IgA and in vitro production of IgA in rheumatoid arthritis

Variation in the serum IgA concentration and the production of IgA in vitro in rheumatoid arthritis treated by sulfasalazine

[Constrictive pericarditis in severe seronegative rheumatoid polyarthritis]

[Hip and spinal ossification enthesopathies induced by etretinate therapy in peripheral psoriatic arthritis]

Radiologic progression in early rheumatoid arthritis treated with methotrexate

Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients

Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients

Methotrexate as the initial second-line disease modifying agent in the treatment of rheumatoid arthritis patients

Study of eight cases of cancer in 426 rheumatoid arthritis patients treated with methotrexate

Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study

Association of methotrexate and corticosteroids in the treatment of patients with rheumatoid arthritis

Possible role of methotrexate in the distal tibiae fractures in a patient with rheumatoid arthritis

Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis

Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients

A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM

Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients

Correlation between methotrexate pharmacokinetic parameters, and clinical and biological status in rheumatoid arthritis patients

Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis

Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients

Performance of Edmonton Frail Scale on frailty assessment: its association with multi-dimensional geriatric conditions assessed with specific screening tools

Impact of regulatory events on JAK inhibitor prescribing in rheumatoid arthritis: Insights from the French MAJIK Registry

Association of systemic lupus erythematosus and choriocarcinoma: a role of hormonal immunomodulation?

Sicca syndrome associated with hepatitis C virus infection